Nelarabine 121032-29-9
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
297.27 Nelarabine is a purine nucleoside analog and DNA Synthesis Inhibitor with IC50 from 0.067-2.15 μM in tumor cells.
Biological Activity
The IC50 of Nelarabine is 25-fold and 113-fold higher than ARAC in T-
and B-lineage, respectively. T-ALL cells are eightfold more sensitive to
Nelarabine than B-lineage but there is considerable overlap. The
efficacy of NEL in T-lineage and B-lineage cell lines is 25-fold and
113-fold less than ARAC, respectively.
Nelarabine acts by inhibiting DNA synthesis and inducing Apoptosis in susceptible cells. Nelarabine demonstrated significant antineoplastic activity with acceptable toxicity.
The Nelarabine plasma AUC is 2.82 mM minutes and the ara-G plasma AUC is
20 mM minutes. The terminal half-life of Nelarabine in plasma is 25
min, clearance is 42 mL/minutes/kg, and central volume of distribution
is 1.1 L/kg. The terminal half-life of ara-G in plasma is 182 minutes
and the central volume of distribution is 1.4 L/kg.
In CSF the terminal
half-life of Nelarabine is 77 minutes and of ara-G is 232 minutes. The
AUCcsf:AUCplasma is 29 % for Nelarabine and 23 % for ara-G. Nelarabine
and ara-G do not accumulate with daily infusions because of their
relatively short half-lives.
Contact us if you need more details on 121032-29-9. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Nelarabine 121032-29-9、121032-29-9 Nelarabine. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
297.27 Nelarabine is a purine nucleoside analog and DNA Synthesis Inhibitor with IC50 from 0.067-2.15 μM in tumor cells.
Biological Activity
The IC50 of Nelarabine is 25-fold and 113-fold higher than ARAC in T-
and B-lineage, respectively. T-ALL cells are eightfold more sensitive to
Nelarabine than B-lineage but there is considerable overlap. The
efficacy of NEL in T-lineage and B-lineage cell lines is 25-fold and
113-fold less than ARAC, respectively.
Nelarabine acts by inhibiting DNA synthesis and inducing Apoptosis in susceptible cells. Nelarabine demonstrated significant antineoplastic activity with acceptable toxicity.
The Nelarabine plasma AUC is 2.82 mM minutes and the ara-G plasma AUC is
20 mM minutes. The terminal half-life of Nelarabine in plasma is 25
min, clearance is 42 mL/minutes/kg, and central volume of distribution
is 1.1 L/kg. The terminal half-life of ara-G in plasma is 182 minutes
and the central volume of distribution is 1.4 L/kg.
In CSF the terminal
half-life of Nelarabine is 77 minutes and of ara-G is 232 minutes. The
AUCcsf:AUCplasma is 29 % for Nelarabine and 23 % for ara-G. Nelarabine
and ara-G do not accumulate with daily infusions because of their
relatively short half-lives.
Contact us if you need more details on 121032-29-9. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Nelarabine 121032-29-9、121032-29-9 Nelarabine. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : DNA Damage > DNA/RNA Synthesis Inhibitor
Premium Related Products
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9